Story perspectives

Parabilis Raises $670M, Shares Jump 58% in Record Biotech IPO

6/13/2026

49 11

Summary

Parabilis Sets Record

Parabilis Medicines raised $670 million in its Nasdaq debut, setting a new record for a venture-backed biotech IPO.
The shares closed the first day at $31.60, a 58% rise above the $20.00 IPO price.
The offering included a concurrent $75 million private placement from Regeneron.
Analysts said the biotech IPO window has reopened, noting Parabilis’ strong debut contrasts with Kailera Therapeutics’ 24% share decline since its April IPO.

Summary

Parabilis Raises Capital

In the desmoid-tumor study, all 25 patients on zolucatetide showed tumor reductions, with about 74% achieving an objective response.
Parabilis earmarked $150 million for the Phase III desmoid-tumor trial, $120 million for other indications and $190 million for additional pipeline programs.
Regeneron agreed to buy over 4 million Parabilis shares at $18 each in a private placement.
Parabilis reported a net loss of $145 million for the prior year, with R&D expenses rising to $125 million.

History

Historical Context

Genentech, founded in 1976 by Robert Swanson and Herbert Boyer, became the world’s first biotechnology firm to list on Nasdaq in 1991 after Roche took a majority stake in 1990. Its successful public debut sparked a wave of biotech offerings, a pattern Parabilis followed with its own Nasdaq offering in 2024, seeking fresh capital for desmoid-tumor therapies.

1 of 3

Parabilis Sets Record

Parabilis Medicines raised $670 million in its Nasdaq debut, setting a new record for a venture-backed biotech IPO.
The shares closed the first day at $31.60, a 58% rise above the $20.00 IPO price.
The offering included a concurrent $75 million private placement from Regeneron.
Analysts said the biotech IPO window has reopened, noting Parabilis’ strong debut contrasts with Kailera Therapeutics’ 24% share decline since its April IPO.

1 / 3